source
- Neurocrine launches new safety study after another death linked to Prader-Willi drug VykatNeurocrine Biosciences announced it will start a new study to evaluate dosing and safety of its rare disease drug Vykat in patients with Prader-Willi syndrome who have complex health issues. The m…
- Rhythm Pharmaceuticals expands LG Chem obesity drug license, total payout up to $855 millionRhythm Pharmaceuticals and LG Chem have revised their licensing agreement for the oral obesity and hyperphagia drug bivamelagon, increasing the total scheduled payments. The new terms raise the po…